SAFETY AND ANTITUMOR ACTIVITY OF DOSTARLIMAB IN PATIENTS (PTS) WITH ADVANCED OR RECURRENT DNA MISMATCH REPAIR DEFICIENT (DMMR) OR PROFICIENT (MMRP) ENDOMETRIAL CANCER (EC): RESULTS FROM THE GARNET STUDY

被引：1

作者：

Oaknin, Ana ^{[1
]}

Gilbert, Lucy ^{[2
]}

Tinker, Anna V. ^{[3
]}

Sabatier, Renaud ^{[4
,5
]}

Boni, Valentina ^{[6
]}

O'malley, David M. ^{[7
]}

Ghamande, Sharad ^{[8
]}

Guo, Wei ^{[9
]}

Im, Ellie ^{[9
]}

Pothuri, Bhavana ^{[10
]}

机构：

[1] Vall Dhebron Univ Hosp, Vall Dhebron Inst Oncol Vhio, Barcelona, Spain

[2] McGill Univ, Hlth Ctr Ri, Montreal, PQ, Canada

[3] Bc Canc, Vancouver, BC, Canada

[4] Aix Marseille Univ, Inst Paoli Calmettes, Marseille, France

[5] Dept Med Oncol, Marseille, France

[6] Hosp Univ Hm Sanchinarro, CtrIntegral Oncol Clara Campal, Barcelona, Spain

[7] Ohio State Univ, James CCC, Columbus, OH 43210 USA

[8] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA

[9] GlaxoSmithKline, New York, NY USA

[10] NYU, Dept Obstet & Gynecol, New York, NY 10003 USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2020年 / 30卷

关键词：

D O I：

10.1136/ijgc-2020-ESGO.71

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

385

引用

页码：A39 / A40

页数：2

共 50 条

[1] Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET
Oaknin, A.
Gilbert, L.
Tinker, A. V.
Sabatier, R.
Boni, V.
O'Malley, D. M.
Ghamande, S.
Duska, L.
Ghatage, P.
Guo, W.
Im, E.
Pothuri, B.
ANNALS OF ONCOLOGY, 2020, 31 : S1166 - S1166
[2] Dostarlimab in advanced/recurrent (A/R) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study
Oaknin, Ana
Pothuri, Bhavana
Gilbert, Lucy
Sabatier, Renaud
Ghamande, Sharad
Gravina, Adriano
Calvo, Emiliano
Banerjee, Susana
Mangan, Niamh
Miller, Rowan E.
Pikiel, Joanna
Mirza, Mansoor R.
Duan, Tao
Zildjian, Sybil
Zografos, Eleftherios
Veneris, Jennifer
Tinker, Anna V.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 133 - 134
[3] Antitumor activity of dostarlimab in patients with advanced or recurrent mismatch repair-deficient or -proficient cancer by prior therapy: Results from the GARNET study
Hanker, Lars
Oaknin, Ana
Gilbert, Lucy
Tinker, Anna
Brown, Jubilee
Matthews, Cara
Press, Joshua
Sabatier, Renaud
O'malley, David
Samouelian, Vanessa
Boni, Valentina
Duska, Linda
Ghamande, Sharad
Ghatage, Prafull
Kristeleit, Rebecca
Leath, Charles, III
Veneris, Jennifer
Duan, Tao
Im, Ellie
Pothuri, Bhavana
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 56 - 56
[4] Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study.
Oaknin, Ana
Pothuri, Bhavana
Gilbert, Lucy
Sabatier, Renaud
Ghamande, Sharad A.
Gravina, Adriano
Calvo, Emiliano
Banerjee, Susana N.
Miller, Rowan
Pikiel, Joanna
Mirza, Mansoor Raza
Duan, Tao
Zildjian, Sybil
Zografos, Eleftherios
Veneris, Jennifer Taylor
Tinker, Anna
Powell, Matthew A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[5] ANTITUMOR ACTIVITY OF DOSTARLIMAB IN PATIENTS WITH ADVANCED OR RECURRENT MISMATCH REPAIR-DEFICIENT OR PROFICIENT-CANCER BY PRIOR THERAPY: RESULTS FROM THE GARNET STUDY
Oaknin, A.
Gilbert, L.
Tinker, A.
Brown, J.
Mathews, C.
Press, J.
Sabatier, R.
O'Malley, D.
Samouelian, V.
Boni, V.
Duska, L.
Ghamande, S.
Ghatage, P.
Kristeleit, R.
Leath, C., III
Veneris, J.
Duan, T.
Im, E.
Pothuri, B.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A2 - A2
[6] The time course of adverse events (AEs) during dostarlimab treatment in mismatch mutation repair deficient (dMMR) and proficient (MMRp) endometrial cancer (EC) patients in the GARNET trial
Banerjee, Ashish
Oaknin, Ana
Gilbert, Lucy
Guo, Wei
Im, Ellie
Pothuri, Bhavana
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 162 - 162
[7] Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, single-arm study
Oaknin, Ana
Gilbert, Lucy
Tinker, Anna, V
Brown, Jubilee
Mathews, Cara
Press, Joshua
Sabatier, Renaud
O'Malley, David M.
Samouelian, Vanessa
Boni, Valentina
Duska, Linda
Ghamande, Sharad
Ghatage, Prafull
Kristeleit, Rebecca
Leath, Charles, III
Guo, Wei
Im, Ellie
Zildjian, Sybil
Han, Xinwei
Duan, Tao
Veneris, Jennifer
Pothuri, Bhavana
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
[8] Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial
Andre, Thierry
Banerjee, Susana
Berton, Dominique
Ellard, Susan L.
Jimenez, Begona
Samouelian, Vanessa
Gilbert, Lucy
Boni, Valentina
Han, Xinwei
Antony, Grace
Veneris, Jennifer
Oaknin., Ana
CANCER RESEARCH, 2022, 82 (12)
[9] Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial
Vogel, Arndt
Andre, Thierry
Banerjee, Susana
Berton, Dominique
Ellard, Susan L.
Jimenez, Begona
Samouelian, Vanessa
Gilbert, Lucy
Boni, Valentina
Han, Xinwei
Antony, Grace
Veneris, Jennifer
Oaknin, Ana
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 17 - 17
[10] Interim analysis of the immune-related endpoints of the mismatch repair deficient (dMMR) and proficient (MMRp) endometrial cancer (EC) cohorts from the GARNET study
Banerjee, Ashish
Oaknin, Ana
Gilbert, Lucy
Tinker, Anna
Sabatier, Renaud
Boni, Valentina
O'Malley, David
Ghamande, Sharad
Duska, Linda
Ghatage, Prafull
Guo, Wei
Im, Ellie
Pothuri, Bhavana
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 161 - 162

← 1 2 3 4 5 →